Drug Approval | August 06, 2023
Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
The product is being launched in August 2023
The product is being launched in August 2023
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
The company has reported total income of Rs. 1248.51 crores during the period ended June 30, 2023
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
Subscribe To Our Newsletter & Stay Updated
